AbbVie (ABBV) Stock Dips as $10.9B Apogee Therapeutics Acquisition Nears Completion

AbbVie (ABBV) stock dropped 2% on a $10.9B Apogee deal. JPMorgan calls it strategic. Learn why analysts back this immunology pipeline expansion.

The post AbbVie (ABBV) Stock Dips as $10.9B Apogee Therapeutics Acquisition Nears Completion appeared first on Blockonomi.